GTG completes $3m share purchase plan
04 October, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has completed the SPP stage of its capital raising and revealed that underwriter Cygnetl has committed to buy an extra $1m worth of shares.
Prima re-evaluating CVac trial design
04 October, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) is re-evaluating using PFS as a primary objective of an upcoming trial of its CVac cancer immunotherapy candidate, based on results to date of an earlier study.
Former Alchemia CEO joins Ascend as chairman
03 October, 2013 by Dylan Bushell-EmblingDr Peter Smith, former CEO of Alchemia (ASX:ACL), has joined Ascend Biopharmaceuticals as its board chairman.
Research Alliance calls for strategic research policy
02 October, 2013Research Alliance advocates for science, research and innovation to have steady and purposeful support.
Vic biotechs win out in Technology Voucher program
27 September, 2013 by Dylan Bushell-EmblingThe Victorian Government has awarded Technology Development vouchers worth up to $50K for 10 high-tech projects, including research into potential treatments for Crohn's disease.
Linking immunity and cancer progression
27 September, 2013An explanation for how a subset of ovarian cancers block the body's early anti-tumour immune response may expand treatment options for patients.
New cancer drugs threaten to stretch PBS thin
24 September, 2013 by Dylan Bushell-EmblingAdvancements in fighting cancer are also driving up the cost of cancer drugs, which could present a major strain on PBS resources, according to Flinders University’s Michael Sorich.
Bioniche to raise $10m through equity offer
20 September, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) has launched a $10m capital raising in Canada to ensure it has funds to continue development of cancer treatment Urocidin while it sells its animal health unit.
Creative prize for early-career researchers
19 September, 2013Applications are open for The Centenary Institute Lawrence Creative Prize for early-career biomedical researchers.
Viralytics meets primary goal of melanoma trial
19 September, 2013 by Dylan Bushell-EmblingA phase II trial of Viralytics' (ASX:VLA) Cavatak cancer-targeting virus in late-stage melanoma is still recruiting patients but has already met its primary endpoint.
New government, no science portfolio
17 September, 2013The incoming ministry for the newly elected Australian Government has been unveiled.
Patrys antibody gets orphan drug status in myeloma
12 September, 2013 by Dylan Bushell-EmblingPatrys's (ASX:PAB) anticancer antibody, PAT-SM6, has been granted orphan drug designation in the EU for bone marrow cancer multiple myeloma.
Starpharma developing new chemotherapy formulation
11 September, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) will advance dendrimer-oxaliplatin into development, after lab trials indicate its version of the chemotherapy drug can be more effective and reduces toxicity.
Viralytics cleared to begin UK cancer trial
11 September, 2013 by Dylan Bushell-EmblingThe UK's MHRA has given its final approval for a phase I/II study of Viralytics' oncolytic virus in melanoma, prostate, lung or metastatic bladder cancers.
ResMed completes recruitment for heart failure trial
06 September, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) has signed up all 1325 patients for what it is billing as the world's largest study of sleep-disordered breathing therapy in at-risk heart failure patients.
